home | publications


1. p63 Expression Profile in Normal and Malignant Prostate Epithelial Cells.
Davis LD, Zhang W, Merseburger AS, Young D, Xu LL, Rhim JS, Moul JW, Srivastava S and Sesterhenn IA.
Anticancer Research, 22:3819-3826, 2002.

2. HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells.
Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S:
Cancer Res. 62(23): 6812-6, 2002.

3. Androgen-Induced Expression of Endoplasmic Reticulum (ER) Stress Response Genes in Prostate Cancer Cells.
Segawa T, Nau M, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul, Judd W, Vahey M, and Srivastava S.
Oncogene, 21, 2002.

4. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.
Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Prostate Cancer and Prostatic Diseases. 5: 212-218, 2002.

5. Investigating the distribution of prostate cancer using three-dimensional computer simulation.
Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW and Lynch JH:
Prostate Cancer and Prostatic Diseases. 5:204-209, 2002.

6. Molecular Markers in Prostate Cancer: The Role in Preoperative Staging.
Moul JW, Merseburger A, Srivastava S:
Clinical Prostate Cancer 1:42-50, 2002.

7. Improved Prostate Cancer-Specific Survival and Other Disease Parameters: Impact of Prostate-Specific Testing.
Paquette E, Sun L. Paquette LR, Connelly R, McLeod DG, and Moul JW:
Urology 60:756-759, 2002.

8. Maspin Expression Profile in Human Prostate Cancer (CaP) and in vitro induction of Maspin expression by Androgen Ablation.
Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S and Sesterhenn I.
Clinical Cancer Research 8:1172-1177, 2002.

9. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM, Torrens JI, Harding P, Howard RS, Duncan WE and McLeod DG:
Prostate Cancer and Prostatic Diseases. 5:304-310, 2002.

10. Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Koff SG, Connelly RR, Bauer JJ, McLeod DG, and Moul JW:
Prostate Cancer and Prostatic Diseases. 5:152-158, 2002.

11. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > 40 ng/mL.
Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, and Moul JW:
Urol. Onc. 7:167-172, 2002.

12. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1024-38,1042; discussion 1042, 1047-8, 1051, 2002.

13. Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis.
Henderson CG, Griewe GL, Siegel TS, Peppas DS, Esther TA, Moul JW:
J Urol. 168:638-9, 2002.

14. Curcumin Down-Regulates AR Gene Expression and Activation in Prostate Cancer Cell Lines.
Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S and Rhim JS:
Int J of Oncol., 21:825-830, 2002.

15. A novel gene DERPC located on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors.
Sun M, Ma L, Xu L, Li J, Zhang W, Petrovics G, Makarem M, Sesterhenn I, Zhang M, Blanchette-Mackie EJ, Moul JW, Srivastava S and Zou Z:
Molecular Medicine 8: 654-662, 2002.

16. Cadmium-induced neoplastic transformation of human prostate epithelial cells.
Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, Srivastava S, Rhim JS.
Int J Oncol. 20:543-7, 2002.

17. Prostate biopsy quantitative histology as a staging and prognostic factor.
Moul JW.
J Urol. 167:526-7, 2002.

18. Outcome research: prostate cancer databases.
Moul JW:
Urol Oncol, 7:39-42, 2002.

19. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1218-24, 2002.

20. Contralateral testicular biopsy procedure in-patients with unilateral testis cancer: is it indicated?
Heidenreich A, Moul JW:
Semin Urol Oncol, 20:234-8, 2002.

21. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer.
Taylor JA, Gancarczyk KJ, Fant GV, McLeod DG.
Urology, 60(5):841-5, 2002.

22. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL.
Radiology, 225:420-6, 2002.

23. Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares.
Moul JW:
Cancer, 95:211-4, 2002.

24. Initiation of salvage therapy for prostate cancer.
Johnstone PA, Booth R, Riffenburgh RH, Amling CL, Kane CJ, Moul JW:
Prostate Cancer Prostatic Dis, 5:136-43, 2002.

25. Adenocarcinoma of the prostate: an expensive way to die.
Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T:
Prostate Cancer Prostatic Dis, 5:164-6, 2002.

26. Emerging role of adjuvant hormonal therapy.
McLeod DG.
Urology, 60(3 Suppl 1):13-20, 2002.

27. Overview consensus statement. Newer Approaches to androgen deprivation therapy in prostate cancer. The 2nd International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer.
Carroll PR, Kantoff PW, Balk SP, Brown MA D’amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C.
Urology, 60(3 Suppl 1):1-6, 2002.

28. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA, Wirth MP, McLeod DG, et al.,
J Urol. 168:429-35, 2002.

29. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D and Rich NM.
Surgery, 132:213-9, 2002.

30. Diagnostic accuracy of prostate needle biopsy.
Donahue T, Moul J:
Curr Urol Rep, 3:215-21, 2002.

31. Molecular Dissection of the Prostate Cancer Genome.
Srikantan, V, and Srivastava S: R. Hoffman and A Heidenreich,
eds. In Prostate Cancer, Diagnosis and Surgical Treatment, Springer-Verlag, 25-40. 2002.